Vision-DMD Project (@vision_dmd) 's Twitter Profile
Vision-DMD Project

@vision_dmd

Project aiming to advance clinical development of orphan drug Vamorolone for treatment of DMD.

ID: 784352898230718464

linkhttp://www.vision-dmd.info calendar_today07-10-2016 11:21:18

217 Tweet

487 Followers

144 Following

Vision-DMD Project (@vision_dmd) 's Twitter Profile Photo

📍 New VISION-DMD White Paper: Returning Individual Clinical Trial Results Back To Patients. It focuses on addressing the ethical and technical challenges, using the vamorolone clinical trial experience. #clinicaltrials #scicomm #medtech vision-dmd.info/return-of-pati…

📍 New VISION-DMD White Paper: Returning Individual Clinical Trial Results Back To Patients. It focuses on addressing the ethical and technical challenges, using the vamorolone clinical trial experience.
#clinicaltrials #scicomm #medtech 
vision-dmd.info/return-of-pati…
Hélène Le Borgne (@helenelborgne) 's Twitter Profile Photo

Thanks #EUfunded @EJPRareDiseases research co-fund for advertising this White Paper of #EUfunded research Vision-DMD Project project: returning individual clinical trial results back to patients - important not only for rare disease patients ! Horizon 2020 #ResearchImpactEU

Vision-DMD Project (@vision_dmd) 's Twitter Profile Photo

Today, Santhera and ReveraGen BioPharma announce topline results with Vamorolone in pivotal VISION-DMD study. Santhera will hold a conference call / webcast today at 16:00 CEST, 15:00 BST, 10:00 EDT. Details: globenewswire.com/news-release/2…

Vision-DMD Project (@vision_dmd) 's Twitter Profile Photo

The power of collaboration: Positive results in VISION DMD study funded by #Horizon2020, #DMD #PatientGroups and US Gov – we are now entering the final phase towards Market Authorisation @santhera ReveraGen BioPharma EU Research Results EU Science & Innovation 🇪🇺 #WDAD2021

The power of collaboration: Positive results in VISION DMD study funded by #Horizon2020, #DMD #PatientGroups and US Gov – we are now entering the final phase towards Market Authorisation @santhera <a href="/ReveraGen/">ReveraGen BioPharma</a>  <a href="/CORDIS_EU/">EU Research Results</a>  <a href="/EUScienceInnov/">EU Science & Innovation 🇪🇺</a> #WDAD2021
World Duchenne Organization (@worldduchenne) 's Twitter Profile Photo

🚨 Important notice on 'stem cell therapy for Duchenne'. Please RT! → Currently, there are no approved stem cell therapies for #Duchenne → You NEVER pay for a clinical trial → If a ‘trial’ is not on clinicaltrials.gov, it is not a legitimate trial worldduchenne.org/news/warning-o…

World Duchenne Organization (@worldduchenne) 's Twitter Profile Photo

💬 What is the patient perspective on returning individual clinical trial data back to participants after a trial has ended? Help Vision-DMD Project answer this question. Please complete this short 4-minute survey 👇 worldduchenne.org/news/return-of… #Duchenne #ClinicalTrial #HealthData

World Duchenne Organization (@worldduchenne) 's Twitter Profile Photo

Throughout the study, Vamorolone: → Showed sustained efficacy across multiple endpoints over 48 weeks → Good safety and tolerability profile was confirmed More about the topline results from the Vision-DMD Project study 👇 worldduchenne.org/news/topline-r…

Duchenne Data Foundation (@duchennedf) 's Twitter Profile Photo

Eric Hoffman, Suzanne Gaglianone Suzanne Gaglianone from ReveraGen BioPharma and Ritchie Head from Ceratium share their experience on what Patient Organizations can do to have data return from clinical trials #DPA2021 #duchenne

Eric Hoffman, Suzanne Gaglianone <a href="/smgag19/">Suzanne Gaglianone</a> from <a href="/ReveraGen/">ReveraGen BioPharma</a> and Ritchie Head from Ceratium share their experience on what Patient Organizations can do to have data return from clinical trials
#DPA2021 #duchenne
Duchenne Data Foundation (@duchennedf) 's Twitter Profile Photo

''Patients want their data returned after a clinical trial'' Ritchie Head from Ceratium, is talking about the patients preferences on the return of their data following a clinical trial. #DPA2021 #duchenne

''Patients want their data returned after a clinical trial'' Ritchie Head from Ceratium, is talking about the patients preferences on the return of their data following a clinical trial.
#DPA2021 #duchenne
Vision-DMD Project (@vision_dmd) 's Twitter Profile Photo

The VISION-DMD project is proud to announce ' Santhera have Received Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy' Read the press release here CHMP-press-release.pdf (vision-dmd.info)